orkambi- lumacaftor and ivacaftor tablet, film coated orkambi- lumacaftor and ivacaftor granule
vertex pharmaceuticals incorporated - lumacaftor (unii: egp8l81apk) (lumacaftor - unii:egp8l81apk), ivacaftor (unii: 1y740ill1z) (ivacaftor - unii:1y740ill1z) - lumacaftor 200 mg - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene. if the patient's genotype is unknown, an fda-cleared cf mutation test should be used to detect the presence of the f508del mutation on both alleles of the cftr gene. limitations of use the efficacy and safety of orkambi have not been established in patients with cf other than those homozygous for the f508del mutation. none. risk summary there are limited and incomplete human data from clinical trials and postmarketing reports on use of orkambi or its individual components, lumacaftor or ivacaftor, in pregnant women to inform a drug-associated risk. in animal reproduction studies, oral administration of lumacaftor to pregnant rats and rabbits during organogenesis demonstrated no teratogenicity or adverse effects on fetal development at doses that produced maternal exposures up to approximately 8 (rats) and 5 (rabbits) times the exposure at the maxim
maca 500 mg capsulas
emceta international, inc - maca - maca....500.00 mg.
orkambi 200/125 lumacaftor/ivacaftor 200mg/125mg film-coated tablet blister pack
vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 125 mg; lumacaftor, quantity: 200 mg - tablet, film coated - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; microcrystalline cellulose; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350; cochineal; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.
orkambi 150/188 lumacaftor/ivacaftor 150mg/188mg granules sachet
vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 150 mg; ivacaftor, quantity: 188 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.
orkambi 100/125 lumacaftor/ivacaftor 100mg/125mg granules sachet
vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 100 mg; ivacaftor, quantity: 125 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.
maca capsule 300mg
kin bio sdn. bhd. - maca (lepidium meyenii) -
sitagliptin pharmacare 25 mg film-coated tablets
pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 25 mg - drugs used in diabetes
sitagliptin pharmacare 50 mg film-coated tablets
pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 50 mg - drugs used in diabetes
sitagliptin pharmacare 100 mg film-coated tablets
pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes
sunitinib pharmacare 12.5 mg hard capsules
pharmacare premium limited hhf 003 halfar industrial estate birzebbugia bbg 3000, malta - hard capsule - sunitinib 12.5 mg - antineoplastic agents